CL2014002935A1 - Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador - Google Patents

Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador

Info

Publication number
CL2014002935A1
CL2014002935A1 CL2014002935A CL2014002935A CL2014002935A1 CL 2014002935 A1 CL2014002935 A1 CL 2014002935A1 CL 2014002935 A CL2014002935 A CL 2014002935A CL 2014002935 A CL2014002935 A CL 2014002935A CL 2014002935 A1 CL2014002935 A1 CL 2014002935A1
Authority
CL
Chile
Prior art keywords
laquinimod
treat
carrier
dosage form
multiple sclerosis
Prior art date
Application number
CL2014002935A
Other languages
English (en)
Spanish (es)
Inventor
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2014002935A1 publication Critical patent/CL2014002935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CL2014002935A 2012-05-02 2014-10-29 Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador CL2014002935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02

Publications (1)

Publication Number Publication Date
CL2014002935A1 true CL2014002935A1 (es) 2015-03-06

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002935A CL2014002935A1 (es) 2012-05-02 2014-10-29 Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador

Country Status (21)

Country Link
US (3) US20130303569A1 (OSRAM)
EP (1) EP2844255A4 (OSRAM)
JP (2) JP2015515985A (OSRAM)
KR (1) KR20150013658A (OSRAM)
CN (2) CN105832733A (OSRAM)
AR (1) AR090885A1 (OSRAM)
AU (1) AU2013256352A1 (OSRAM)
BR (1) BR112014027010A2 (OSRAM)
CA (1) CA2870684A1 (OSRAM)
CL (1) CL2014002935A1 (OSRAM)
EA (1) EA201492010A1 (OSRAM)
HK (1) HK1206246A1 (OSRAM)
IL (1) IL235337A0 (OSRAM)
MX (1) MX2014013039A (OSRAM)
PE (1) PE20150161A1 (OSRAM)
PH (1) PH12014502447A1 (OSRAM)
SG (1) SG11201406594UA (OSRAM)
TW (2) TW201804997A (OSRAM)
UY (1) UY34775A (OSRAM)
WO (1) WO2013166166A1 (OSRAM)
ZA (1) ZA201408820B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
JP7724151B2 (ja) * 2018-07-20 2025-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ－ピリミジン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
PL1797109T3 (pl) * 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD

Also Published As

Publication number Publication date
CA2870684A1 (en) 2013-11-07
ZA201408820B (en) 2016-06-29
EP2844255A1 (en) 2015-03-11
TW201804997A (zh) 2018-02-16
HK1206246A1 (en) 2016-01-08
US20160000775A1 (en) 2016-01-07
PE20150161A1 (es) 2015-02-22
TW201347762A (zh) 2013-12-01
JP2015515985A (ja) 2015-06-04
CN104284663A (zh) 2015-01-14
PH12014502447A1 (en) 2015-01-12
EP2844255A4 (en) 2015-10-14
AR090885A1 (es) 2014-12-10
UY34775A (es) 2013-11-29
KR20150013658A (ko) 2015-02-05
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
CN105832733A (zh) 2016-08-10
AU2013256352A1 (en) 2014-11-27
WO2013166166A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
US20150265592A1 (en) 2015-09-24
IL235337A0 (en) 2014-12-31
US20130303569A1 (en) 2013-11-14
EA201492010A1 (ru) 2015-06-30
MX2014013039A (es) 2015-02-04

Similar Documents

Publication Publication Date Title
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
PH12014500386A1 (en) Combination treatment for hepatitis c
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PH12015500823A1 (en) Modified release formulations for oprozomib
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
IL234093A0 (en) Preparations and dosages for oral administration and their uses for the treatment of Gaucher's disease
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
IN2014DN09240A (OSRAM)
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
EA201200799A1 (ru) Гепатопротекторное средство
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
UA85800U (ru) Способ интенсивной терапии рецидива простой шизофрении с непрерывным течением и агрессивным поведением
RU2012135942A (ru) Способ лечения больных желчекаменной болезнью первой стадии
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia